Early multi-gene sequencing to guide therapy in advanced poor-prognosis cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with unresectable or metastatic pancreatic cancer, liver cancer, or triple-negative breast cancer will be randomized to receive either early large-panel sequencing (including DNA and RNA panels) to guide therapy versus a standard-sequence approach after first-line treatment starts. The study uses molecular tumor board recommendations based on actionable targets (ESCAT II/IV) to decide on possible treatments. It includes evaluation of tumor mutational burden and MMR status, with tissue obtained from a visceral site or surgical sample. If needed, a repeat biopsy may be proposed in Part 2 of the study. The overall aim is to see if early comprehensive sequencing can improve access to targeted therapies and accelerate clinical research in poor-prognosis cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \- Age \>18 years.
* Advanced disease status ("unresectable" or "metastatic").
* Patient included either at the time of diagnostic investigation or during first line of treatment.
* Good general conditions, still compatible with a therapeutic proposal, WHO 0-1.
* The following tumour sites, with poor prognosis and for which ESCAT II/IV treatment targets can be found according to ESMO:

  * pancreatic adenocarcinoma
  * hepatocellular carcinomas,
  * triple negative breast cancer.
* Tumour tissue a priori available in sufficient quantity: at least one biopsy from a visceral metastatic site or surgical specimen (if available) for eligible cancers.
* Patient covered by a social sercurity scheme

Exclusion Criteria:

* \- General condition WHO \>1 and/or nutritional status not compatible with a therapeutic proposal
* Limiting systemic cardiovascular, renal, bronchopulmonary or endocrinological comorbidities with the initiation of a therapeutic proposal
* Active infection or active chronic disease (diabetes, liver dysfunction, immune disease) making the patient's condition incompatible with a therapeutic proposal.
* A priori unavailable, in insufficient quantity or of suboptimal quality tumour material.
* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent.

Where it's running

• Hôpital Claude Huriez - Service Oncologie
  Lille, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

• AI language tools to help tumor care teams write MDT reports

  We will test whether AI language tools can help junior cancer doctors write MDT diagnosis and treatment reports more accurately and faster.

  Recruiting at 2 sites Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 1 other locations · NCT07504367

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.